SCHEMBL2597279

SCHEMBL2597279

CC1(C)CN(c2ncc(C(F)(F)F)cc2Cl)CCC1N1CC[C@H](Nc2ccc(S(C)(=O)=O)cc2F)C1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.42
SLC6A9 P48067 4/20 0.41
KCNH2 Q12809 3/20 0.41
CXCR3 P49682 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
LMNA P02545 1/20 0.39
HSD11B1 P28845 1/20 0.38
CYP2C9 P11712 3/20 0.37
CYP2C19 P33261 3/20 0.37
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 2/20 0.37
HPGD P15428 1/20 0.37
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
MAPT P10636 2/20 0.36
GAA P10253 1/20 0.36
CYP3A4 P08684 1/20 0.36
POLB P06746 1/20 0.36
PTGS1 P23219 1/20 0.36
PTGS2 P35354 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2597280 1.00 GPR119 (0.42) GPR119SLC6A9KCNH2CXCR3SMN1; SMN2
SCHEMBL15022855 0.88 SLC6A9 (0.46) GPR119SLC6A9KCNH2CXCR3SMN1; SMN2
SCHEMBL15022856 0.88 SLC6A9 (0.46) GPR119SLC6A9KCNH2CXCR3SMN1; SMN2
SCHEMBL15023673 0.84 SLC6A9 (0.45) GPR119SLC6A9KCNH2CXCR3SMN1; SMN2
SCHEMBL2597325 0.83 GPR119 (0.36) GPR119SLC6A9KCNH2
SCHEMBL2597324 0.83 GPR119 (0.36) GPR119SLC6A9KCNH2
SCHEMBL12185832 0.81 SLC6A9 (0.46) GPR119SLC6A9KCNH2CXCR3PTGS1
SCHEMBL15022743 0.81 SLC6A9 (0.46) GPR119SLC6A9KCNH2CXCR3PTGS1
SCHEMBL15022662 0.78 GPR119 (0.44) GPR119SLC6A9KCNH2CYP2C9CYP3A4
SCHEMBL12185828 0.78 GPR119 (0.44) GPR119SLC6A9KCNH2CYP2C9CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8754226-B2 Piperidinyl-substituted lactams as GPR119 modulators ARRAY BIOPHARMA INC. (US) 2014-06-17 US disclosed
US-20130158009-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2013-06-20 US disclosed
CN-103080101-A Piperidinyl-substituted lactams as GPR119 modulators ARRAY BIOPHARMA INC 2013-05-01 CN disclosed
EP-2571864-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS Array Biopharma, Inc. (US) 2013-03-27 EP disclosed
WO-2011146335-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS ARRAY BIOPHARMA INC. (US) 2011-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158009-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS GPR119, GPR139, GPR39 GPR119 1/4885SLC6A9 324/4885KCNH2 1430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.